SEC Company Response from ProQR Therapeutics N.V. (PRQR) (CIK 0001612940) (PRQR) — Oct 15, 2015
ProQR Therapeutics N.V. (PRQR) (CIK 0001612940)
Date: Oct. 15, 2015 · CIK: 0001612940 · Accession: 0001193125-15-344711
AI Filing Summary & Sentiment
File numbers found in text: 333-207245
Letter
Acceleration Request
ProQR Therapeutics, N.V.
Darwineg 24
2333 CR Leiden
The Netherlands
VIA EDGAR AND FEDERAL EXPRESS
October 15, 2015
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549-4720
Re: ProQR Therapeutics N.V.
Acceleration Request for Registration Statement on Form F-3
File No. 333-207245
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to October 19, 2015, at 4:00 p.m., Eastern Time, or as soon thereafter as possible.
In connection with the foregoing, the Company hereby acknowledges the following:
•
should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions regarding this request, please contact Danielle M. Lauzon of Goodwin Procter LLP at (617) 570-1955.
Signature Page Follows
Sincerely,
PROQR THERAPEUTICS N.V.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request ProQR Therapeutics, N.V. Darwineg 24 2333 CR Leiden The Netherlands VIA EDGAR AND FEDERAL EXPRESS October 15, 2015 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4720 Re: ProQR Therapeutics N.V. Acceleration Request for Registration Statement on Form F-3 File No. 333-207245 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to October 19, 2015, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. In connection with the foregoing, the Company hereby acknowledges the following: • should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; • the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you have any questions regarding this request, please contact Danielle M. Lauzon of Goodwin Procter LLP at (617) 570-1955. Signature Page Follows Sincerely, PROQR THERAPEUTICS N.V. /s/ Daniel de Boer Daniel de Boer Chief Executive Officer cc: Smital Shah, ProQR Therapeutics N.V. René Beukema, ProQR Therapeutics N.V. Mitchell S. Bloom, Goodwin Procter LLP Danielle M. Lauzon, Goodwin Procter LLP